Key result
Prior renal transplant shows no difference in in-hospital mortality after TAVR.
Why the study?
Data on the safety and clinical outcomes of TAVR in renal and liver transplant patients are limited.
Does transcatheter aortic valve replacement (TAVR) have similar safety and clinical outcomes in patients with a history of renal or liver transplant compared to non-transplant patients?
Cohort (n=62,399)
Yes
Does transcatheter aortic valve replacement (TAVR) have similar safety and clinical outcomes in patients with a history of renal or liver transplant compared to non-transplant patients?
Odds Ratio: 0.61 (95% CI 0.25–1.5)
p-value: p=0.37
TAVR appears to be a safe procedure for patients with a history of renal or liver transplant, with in-hospital mortality and major complication rates similar to those of non-transplant patients.
Reassuring in-hospital mortality data for TAVR after renal transplant; leaves open confirmation in larger cohorts and for longer-term outcomes.
Background: The transcatheter aortic valve replacement (TAVR) has recently gained traction as a viable alternative to surgical aortic valve replacement (SAVR), but data on its safety and clinical outcomes in transplant patients are limited.Methods: We retrieved relevant demographic and clinical outcome data from the U.S. National Inpatient Sample (NIS) for the year 2012–2015. The clinical outcomes of TAVR in renal transplant (RT) and liver transplant (LT) were ascertained using an adjusted odds ratio (aOR) with a 95% confidence interval (CI) on Mantzel–Hensel test.Results: A total of 62,399 TAVR patients were identified; 62,180 (99.6%) with no history of transplant, 219 (0.4%) with RT and 85 (0.1%) with LT. There was no significant difference in odds of in-hospital mortality (OR 0.61, 95% CI 0.25–1.5, p = 0.37), major cardiovascular, respiratory or neurological complications in patients with and without RT. Similarly, the odds of cardiac complications, renal and neurological complications between patients with and without LT were identical.Conclusion: Compared to non-transplant patients, TAVR appears to be associated with similar odds of major systemic complications or mortality in patients with a history of kidney or liver transplant.
No takes yet. Share an insight, caveat, or question.
Ullah et al. (2021) conducted a cohort in Transcatheter aortic valve replacement (TAVR) (n=62,399). History of renal or liver transplant vs. No history of transplant was evaluated on In-hospital mortality (OR 0.61, 95% CI 0.25-1.5, p=0.37). In patients undergoing TAVR, a history of renal transplant was not associated with a significant difference in in-hospital mortality compared to no transplant history (OR 0.61; 95% CI 0.25-1.5; p=0.37).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: